Last Week Omnicell, Inc. (NASDAQ:OMCL) Ratings

May 17, 2018 - By Yee Bell

Omnicell, Inc. (NASDAQ:OMCL) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.12. That’s change of 0.10, from 2017Q3’s 1.02. 14 investors sold all, 72 reduced holdings as Omnicell, Inc. ratio increased. 69 increased holdings while 27 funds amassed holdings. Funds hold 37.38 million shares thus 0.77% more from 2017Q3’s 37.10 million shares.
Mondrian Inv Ptnrs Ltd holds 0.07% or 60,461 shs. 62,677 were accumulated by Teton. Teacher Retirement Of Texas accumulated 0% or 12,877 shs. Shelton Cap Mngmt invested in 9,800 shs or 0.03% of the stock. Moreover, Blackrock has 0.01% invested in Omnicell, Inc. (NASDAQ:OMCL). First Personal Fin accumulated 203 shs. Schwab Charles Invest Mgmt has invested 0.01% in Omnicell, Inc. (NASDAQ:OMCL). 17,416 were accumulated by Envestnet Asset Mgmt. Grisanti Mngmt Limited Com, New York-based fund reported 1,200 shs. Fisher Asset Mgmt Limited Co reported 530,569 shs. 7,561 were accumulated by State Of Alaska Department Of Revenue. Needham Management Lc reported 0.17% in Omnicell, Inc. (NASDAQ:OMCL). Pub Sector Pension Inv Board invested in 23,463 shs or 0.01% of the stock. Torray Lc reported 20,992 shs. 100,542 were reported by Wasatch Advsr.

Omnicell, Inc. registered $1.81 million net activity with 0 insider buys and 7 insider sales since December 15, 2017. Another trade for 11,284 shs valued at $507,248 was sold by JOHNSTON DAN S. On Thursday, March 15 575 shs were sold by PETERSMEYER GARY S, worth $25,544. Seim Robin Gene sold $617,524 worth of Omnicell, Inc. (NASDAQ:OMCL) or 13,286 shs on Tuesday, May 15. $361,938 worth of Omnicell, Inc. (NASDAQ:OMCL) was sold by LIPPS RANDALL A on Tuesday, March 6.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

Total analysts of 4 have positions in Omnicell (NASDAQ:OMCL) as follows: 2 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 50%. Since December 5, 2017 according to StockzIntelligence Inc Omnicell has 7 analyst reports. On Tuesday, December 5 the firm has “Buy” rating by Cantor Fitzgerald given. On Thursday, February 1 the stock of Omnicell, Inc. (NASDAQ:OMCL) has “Buy” rating given by Cantor Fitzgerald. On Tuesday, December 5 Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) rating. Oppenheimer has “Buy” rating and $55.0 target. On Friday, February 2 the firm earned “Neutral” rating by PiperJaffray. On Friday, February 2 the stock of Omnicell, Inc. (NASDAQ:OMCL) has “Hold” rating given by Craig Hallum. On Thursday, April 26 the firm has “Buy” rating given by Cantor Fitzgerald. On Monday, January 29 the firm earned “Buy” rating by Oppenheimer. Listed here are Omnicell, Inc. (NASDAQ:OMCL) PTs and latest ratings.

26/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0000 Maintain
02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain

Ticker’s shares touched $46.35 during the last trading session after 0.65% change.Currently Omnicell, Inc. is uptrending after 5.20% change in last May 17, 2017. OMCL has 224,857 shares volume. OMCL underperformed by 6.35% the S&P500.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.The firm is worth $1.80 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence.87.45 is the P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Another two news for Omnicell, Inc. (NASDAQ:OMCL) were briefly published by: Seekingalpha.com on April 27, 2018 with title “Omnicell’s (OMCL) CEO Randall Lipps on Q1 2018 Results – Earnings Call Transcript”. The other Prnewswire.com‘s article was titled “Omnicell Announces First Quarter 2018 Results” and published on April 26, 2018.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.